EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
